Aurinia Pharmaceuticals Inc

FRA:IKAP (Canada)  
€ 4.54 (+0.33%) Mar 28
At Loss
P/B:
1.90
Market Cap:
€ 669.45M ($ 721.35M)
Enterprise V:
€ 435.56M ($ 469.33M)
Volume:
-
Avg Vol (2M):
2.50K
Also Trade In:

Business Description

Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 3.59
Equity-to-Asset 0.69
Debt-to-Equity 0.26
Debt-to-EBITDA -1.46
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.77
Distress
Grey
Safe
Beneish M-Score -2.8
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 35.11
9-Day RSI 28.27
14-Day RSI 27.77
6-1 Month Momentum % -27.77
12-1 Month Momentum % -47.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.5
Quick Ratio 4.99
Cash Ratio 4.54
Days Inventory 836.79
Days Sales Outstanding 47.44
Days Payable 127.73

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.3
Shareholder Yield % -9.22

Financials (Next Earnings Date:2024-05-03 Est.)

FRA:IKAP's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Aurinia Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 162.87
EPS (TTM) (€) -0.491
Beta 2.18
Volatility % 53.49
14-Day RSI 27.77
14-Day ATR (€) 0.115011
20-Day SMA (€) 4.75875
12-1 Month Momentum % -47.37
52-Week Range (€) 4.425 - 11.2
Shares Outstanding (Mil) 144.62

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aurinia Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Aurinia Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Aurinia Pharmaceuticals Inc Frequently Asked Questions

What is Aurinia Pharmaceuticals Inc(FRA:IKAP)'s stock price today?
The current price of FRA:IKAP is €4.54. The 52 week high of FRA:IKAP is €11.20 and 52 week low is €4.43.
When is next earnings date of Aurinia Pharmaceuticals Inc(FRA:IKAP)?
The next earnings date of Aurinia Pharmaceuticals Inc(FRA:IKAP) is 2024-05-03 Est..
Does Aurinia Pharmaceuticals Inc(FRA:IKAP) pay dividends? If so, how much?
Aurinia Pharmaceuticals Inc(FRA:IKAP) does not pay dividend.

Press Release

Subject Date
No Press Release